229 related articles for article (PubMed ID: 24762293)
1. Successes and challenges in phenotype-based lead discovery for prion diseases.
Ghaemmaghami S; Russo M; Renslo AR
J Med Chem; 2014 Aug; 57(16):6919-29. PubMed ID: 24762293
[TBL] [Abstract][Full Text] [Related]
2. Unique drug screening approach for prion diseases identifies tacrolimus and astemizole as antiprion agents.
Karapetyan YE; Sferrazza GF; Zhou M; Ottenberg G; Spicer T; Chase P; Fallahi M; Hodder P; Weissmann C; Lasmézas CI
Proc Natl Acad Sci U S A; 2013 Apr; 110(17):7044-9. PubMed ID: 23576755
[TBL] [Abstract][Full Text] [Related]
3. Optimization of Aryl Amides that Extend Survival in Prion-Infected Mice.
Giles K; Berry DB; Condello C; Dugger BN; Li Z; Oehler A; Bhardwaj S; Elepano M; Guan S; Silber BM; Olson SH; Prusiner SB
J Pharmacol Exp Ther; 2016 Sep; 358(3):537-47. PubMed ID: 27317802
[TBL] [Abstract][Full Text] [Related]
4. Human cerebral organoids as a therapeutic drug screening model for Creutzfeldt-Jakob disease.
Groveman BR; Ferreira NC; Foliaki ST; Walters RO; Winkler CW; Race B; Hughson AG; Zanusso G; Haigh CL
Sci Rep; 2021 Mar; 11(1):5165. PubMed ID: 33727594
[TBL] [Abstract][Full Text] [Related]
5. An in vivo Caenorhabditis elegans model for therapeutic research in human prion diseases.
Bizat N; Parrales V; Laoues S; Normant S; Levavasseur E; Roussel J; Privat N; Gougerot A; Ravassard P; Beaudry P; Brandel JP; Laplanche JL; Haïk S
Brain; 2021 Oct; 144(9):2745-2758. PubMed ID: 34687213
[TBL] [Abstract][Full Text] [Related]
6. Novel screening approaches for human prion diseases drug discovery.
Moda F; Bolognesi ML; Legname G
Expert Opin Drug Discov; 2019 Oct; 14(10):983-993. PubMed ID: 31271065
[No Abstract] [Full Text] [Related]
7. Prion Strain Characterization of a Novel Subtype of Creutzfeldt-Jakob Disease.
Galeno R; Di Bari MA; Nonno R; Cardone F; Sbriccoli M; Graziano S; Ingrosso L; Fiorini M; Valanzano A; Pasini G; Poleggi A; Vinci R; Ladogana A; Puopolo M; Monaco S; Agrimi U; Zanusso G; Pocchiari M
J Virol; 2017 Jun; 91(11):. PubMed ID: 28298604
[TBL] [Abstract][Full Text] [Related]
8. Applications of the real-time quaking-induced conversion assay in diagnosis, prion strain-typing, drug pre-screening and other amyloidopathies.
Candelise N; Schmitz M; Da Silva Correia SM; Arora AS; Villar-Piqué A; Zafar S; Llorens F; Cramm M; Zerr I
Expert Rev Mol Diagn; 2017 Oct; 17(10):897-904. PubMed ID: 28817974
[TBL] [Abstract][Full Text] [Related]
9. PMCA Applications for Prion Detection in Peripheral Tissues of Patients with Variant Creutzfeldt-Jakob Disease.
Giaccone G; Moda F
Biomolecules; 2020 Mar; 10(3):. PubMed ID: 32151109
[TBL] [Abstract][Full Text] [Related]
10. Profoundly different prion diseases in knock-in mice carrying single PrP codon substitutions associated with human diseases.
Jackson WS; Borkowski AW; Watson NE; King OD; Faas H; Jasanoff A; Lindquist S
Proc Natl Acad Sci U S A; 2013 Sep; 110(36):14759-64. PubMed ID: 23959875
[TBL] [Abstract][Full Text] [Related]
11. Multitarget ligands and theranostics: sharpening the medicinal chemistry sword against prion diseases.
Bongarzone S; Staderini M; Bolognesi ML
Future Med Chem; 2014 Jun; 6(9):1017-29. PubMed ID: 25068985
[TBL] [Abstract][Full Text] [Related]
12. POSCAbilities: The Application of the Prion Organotypic Slice Culture Assay to Neurodegenerative Disease Research.
Pineau H; Sim V
Biomolecules; 2020 Jul; 10(7):. PubMed ID: 32698402
[TBL] [Abstract][Full Text] [Related]
13. Prions from Sporadic Creutzfeldt-Jakob Disease Patients Propagate as Strain Mixtures.
Cassard H; Huor A; Espinosa JC; Douet JY; Lugan S; Aron N; Vilette D; Delisle MB; Marín-Moreno A; Peran P; Beringue V; Torres JM; Ironside JW; Andreoletti O
mBio; 2020 Jun; 11(3):. PubMed ID: 32546613
[TBL] [Abstract][Full Text] [Related]
14. 2-Aminothiazoles with improved pharmacotherapeutic properties for treatment of prion disease.
Li Z; Silber BM; Rao S; Gever JR; Bryant C; Gallardo-Godoy A; Dolghih E; Widjaja K; Elepano M; Jacobson MP; Prusiner SB; Renslo AR
ChemMedChem; 2013 May; 8(5):847-57. PubMed ID: 23509039
[TBL] [Abstract][Full Text] [Related]
15. Human prion diseases: surgical lessons learned from iatrogenic prion transmission.
Bonda DJ; Manjila S; Mehndiratta P; Khan F; Miller BR; Onwuzulike K; Puoti G; Cohen ML; Schonberger LB; Cali I
Neurosurg Focus; 2016 Jul; 41(1):E10. PubMed ID: 27364252
[TBL] [Abstract][Full Text] [Related]
16. 2-Aminothiazoles as therapeutic leads for prion diseases.
Gallardo-Godoy A; Gever J; Fife KL; Silber BM; Prusiner SB; Renslo AR
J Med Chem; 2011 Feb; 54(4):1010-21. PubMed ID: 21247166
[TBL] [Abstract][Full Text] [Related]
17. Recent advances in the histo-molecular pathology of human prion disease.
Baiardi S; Rossi M; Capellari S; Parchi P
Brain Pathol; 2019 Mar; 29(2):278-300. PubMed ID: 30588685
[TBL] [Abstract][Full Text] [Related]
18. Therapies for prion diseases.
Zafar S; Noor A; Zerr I
Handb Clin Neurol; 2019; 165():47-58. PubMed ID: 31727228
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of IL-1β Signaling Normalizes NMDA-Dependent Neurotransmission and Reduces Seizure Susceptibility in a Mouse Model of Creutzfeldt-Jakob Disease.
Bertani I; Iori V; Trusel M; Maroso M; Foray C; Mantovani S; Tonini R; Vezzani A; Chiesa R
J Neurosci; 2017 Oct; 37(43):10278-10289. PubMed ID: 28924012
[TBL] [Abstract][Full Text] [Related]
20. Neuropathological and biochemical criteria to identify acquired Creutzfeldt-Jakob disease among presumed sporadic cases.
Kobayashi A; Parchi P; Yamada M; Mohri S; Kitamoto T
Neuropathology; 2016 Jun; 36(3):305-10. PubMed ID: 26669818
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
